NZ546379A - Nanoparticles for drug delivery - Google Patents
Nanoparticles for drug deliveryInfo
- Publication number
- NZ546379A NZ546379A NZ546379A NZ54637904A NZ546379A NZ 546379 A NZ546379 A NZ 546379A NZ 546379 A NZ546379 A NZ 546379A NZ 54637904 A NZ54637904 A NZ 54637904A NZ 546379 A NZ546379 A NZ 546379A
- Authority
- NZ
- New Zealand
- Prior art keywords
- pharmaceutical composition
- nanoparticle
- peptide
- mono
- polysaccharide
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nanotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Optics & Photonics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US51632403P | 2003-10-31 | 2003-10-31 | |
| PCT/US2004/036172 WO2005041933A1 (en) | 2003-10-31 | 2004-10-28 | Nanoparticles for drug delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ546379A true NZ546379A (en) | 2010-04-30 |
Family
ID=34549527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ546379A NZ546379A (en) | 2003-10-31 | 2004-10-28 | Nanoparticles for drug delivery |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050170004A1 (enExample) |
| EP (1) | EP1680087A1 (enExample) |
| JP (1) | JP2007509981A (enExample) |
| KR (1) | KR20060097020A (enExample) |
| AU (1) | AU2004285553B2 (enExample) |
| CA (1) | CA2541445A1 (enExample) |
| EA (1) | EA200600877A1 (enExample) |
| IL (1) | IL174748A0 (enExample) |
| NZ (1) | NZ546379A (enExample) |
| WO (1) | WO2005041933A1 (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES |
| US6800287B2 (en) * | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| EP1459065B1 (en) * | 2001-12-04 | 2010-07-28 | Teva Pharmaceutical Industries, Ltd. | Processes for the measurement of the potency of glatiramer acetate |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| KR100638041B1 (ko) * | 2003-12-24 | 2006-10-23 | 주식회사 삼양사 | 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법 |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| NZ578727A (en) * | 2004-06-25 | 2011-03-31 | Brigham & Womens Hospital | Proteosome compositions and methods for treating neurological disorders |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| US8324641B2 (en) * | 2007-06-29 | 2012-12-04 | Ledengin, Inc. | Matrix material including an embedded dispersion of beads for a light-emitting device |
| US20060172942A1 (en) * | 2005-02-02 | 2006-08-03 | Teva Pharmaceutical Industries, Ltd. | Process for producing polypeptide mixtures using hydrogenolysis |
| US20060240463A1 (en) * | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
| DE102005044400A1 (de) * | 2005-09-16 | 2007-03-22 | Capsulution Nanoscience Ag | Verfahren zur Verkapselung und kontrollierten Freisetzung von schwer wasserlöslichen (hydrophoben) flüssigen und festen Wirkstoffen |
| AR063704A1 (es) | 2006-09-14 | 2009-02-11 | Makhteshim Chem Works Ltd | Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones |
| WO2008032327A2 (en) * | 2006-09-14 | 2008-03-20 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Organic nanoparticles obtained from microemulsions by solvent evaporation |
| US11246831B2 (en) | 2007-03-30 | 2022-02-15 | Particle Sciences, Inc. | Particle formulations and uses thereof |
| WO2009070298A1 (en) * | 2007-11-28 | 2009-06-04 | Teva Pharmaceutical Industries, Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| IL188647A0 (en) * | 2008-01-08 | 2008-11-03 | Orina Gribova | Adaptable structured drug and supplements administration system (for oral and/or transdermal applications) |
| IN2012DN00311A (enExample) | 2009-07-09 | 2015-05-08 | Oshadi Drug Administration Ltd | |
| ES2351756B1 (es) * | 2009-07-28 | 2011-10-05 | Universidad Del Pais Vasco | Nanopartículas lipídicas para terapia génica. |
| RS55607B1 (sr) | 2009-08-20 | 2017-06-30 | Yeda Research & Development Company Ltd | Niskofrekventna terapija glatiramer acetatom |
| US20120177741A1 (en) * | 2009-09-29 | 2012-07-12 | Eyegate Pharmaceuticals, Inc. | Positively-charged poly (d,l-lactide-co-glycolide) nanoparticles and fabrication methods of the same |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| WO2011080733A1 (en) | 2010-01-04 | 2011-07-07 | Mapi Pharma Limited | Depot systems comprising glatiramer or a pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| US20120039814A1 (en) * | 2010-08-13 | 2012-02-16 | Sample Jennifer L | Topical Compositions and Methods of Detection and Treatment |
| US10758630B2 (en) * | 2010-08-13 | 2020-09-01 | The Johns Hopkins University | Topical compositions and methods of detection and treatment |
| EA025780B1 (ru) | 2010-10-11 | 2017-01-30 | Тева Фармасьютикал Индастриз Лтд. | Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат |
| ES2601892T3 (es) | 2011-04-21 | 2017-02-16 | Mapi Pharma Limited | Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes |
| MX2014004309A (es) | 2011-10-10 | 2015-07-06 | Teva Pharma | Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer. |
| TWI483747B (zh) * | 2012-05-29 | 2015-05-11 | Univ Nat Chiao Tung | 口服式藥物載體及其製備方法 |
| US9724304B2 (en) * | 2012-06-14 | 2017-08-08 | Temple University—Of the Commonwealth System of Higher Education | Nanospheres for therapeutic agent delivery |
| WO2014058976A2 (en) | 2012-10-10 | 2014-04-17 | Teva Pharmaceutical Industries Ltd. | Biomarkers predictive for clinical response for glatiramer acetate |
| CN111544601A (zh) | 2012-10-30 | 2020-08-18 | 粒子科学有限公司 | 具有靶向部分的药物递送粒子制剂 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US10493122B2 (en) * | 2014-03-17 | 2019-12-03 | Mapi Pharma Ltd. | Sublingual delivery of glatiramer acetate |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| AU2017225481A1 (en) * | 2016-03-01 | 2018-09-13 | Fundacio Hospital Universitari Vall D'hebron-Institut De Recerca | System for thermotherapy treatment or prevention of antimicrobial resistant or biofilm infections |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| AU2017319728B2 (en) | 2016-08-31 | 2024-09-05 | Mapi Pharma Ltd | Depot systems comprising glatiramer acetate |
| US11491114B2 (en) | 2016-10-12 | 2022-11-08 | Curioralrx, Llc | Formulations for enteric delivery of therapeutic agents |
| IL316573A (en) | 2017-03-26 | 2024-12-01 | Mapi Pharma Ltd | Storage systems containing glatiramer acetate for the treatment of multiple sclerosis |
| JP2024509950A (ja) | 2021-03-11 | 2024-03-05 | 89バイオ,インコーポレイテッド | 変異体fgf-21ペプチドpeg化コンジュゲートを含む液体製剤 |
| CN117120070B (zh) * | 2021-03-11 | 2024-11-15 | 89生物公司 | 包含突变型fgf-21肽peg化缀合物的液体制剂 |
| US11878025B2 (en) * | 2021-09-06 | 2024-01-23 | Slayback Pharma Llc | Pharmaceutical compositions of mifepristone |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| AU658608B2 (en) * | 1991-03-25 | 1995-04-27 | Astellas Pharma Europe B.V. | Topical preparation containing a suspension of solid lipid particles |
| US5336507A (en) * | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
| US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US5858964A (en) * | 1995-04-14 | 1999-01-12 | Yeda Research And Development Co. Ltd. | Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD |
| ES2093562B1 (es) * | 1995-05-26 | 1997-07-01 | Univ Santiago Compostela | Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido. |
| JP2001503735A (ja) * | 1996-07-03 | 2001-03-21 | ユニバーシティ オブ ピッツバーグ | 親水性活性試薬のためのエマルジョン処方物 |
| US7255877B2 (en) * | 1996-08-22 | 2007-08-14 | Jagotec Ag | Fenofibrate microparticles |
| US6465016B2 (en) * | 1996-08-22 | 2002-10-15 | Research Triangle Pharmaceuticals | Cyclosporiine particles |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| US6537246B1 (en) * | 1997-06-18 | 2003-03-25 | Imarx Therapeutics, Inc. | Oxygen delivery agents and uses for the same |
| US6638621B2 (en) * | 2000-08-16 | 2003-10-28 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
| US20030170313A1 (en) * | 1997-10-09 | 2003-09-11 | Ales Prokop | Micro-particulate and nano-particulate polymeric delivery system |
| US7101575B2 (en) * | 1998-03-19 | 2006-09-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Production of nanocapsules and microcapsules by layer-wise polyelectrolyte self-assembly |
| AU761205B2 (en) * | 1998-03-30 | 2003-05-29 | Skyepharma Canada Inc. | Composition and method of preparing microparticles of water-insoluble substances |
| DE19819273A1 (de) * | 1998-04-30 | 1999-11-11 | Pharmatec International S Giul | Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung |
| US6514938B1 (en) * | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| US6355270B1 (en) * | 1999-01-11 | 2002-03-12 | The Regents Of The University Of California | Particles for oral delivery of peptides and proteins |
| US6355271B1 (en) * | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6761903B2 (en) * | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
| US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
| CA2372461A1 (en) * | 1999-05-07 | 2000-11-16 | Pharmasol Gmbh | Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates |
| US6458383B2 (en) * | 1999-08-17 | 2002-10-01 | Lipocine, Inc. | Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US7195780B2 (en) * | 2002-10-21 | 2007-03-27 | University Of Florida | Nanoparticle delivery system |
| US6482439B2 (en) * | 1999-12-29 | 2002-11-19 | Nanodelivery, Inc. | Drug delivery system exhibiting permeability control |
| DE10001172A1 (de) * | 2000-01-13 | 2001-07-26 | Max Planck Gesellschaft | Templatieren von Feststoffpartikeln mit Polymermultischichten |
| US7022663B2 (en) * | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| SE0002822L (sv) * | 2000-08-04 | 2002-01-29 | Microdrug Ag | Elektropulver |
| US6887493B2 (en) * | 2000-10-25 | 2005-05-03 | Adi Shefer | Multi component controlled release system for oral care, food products, nutraceutical, and beverages |
| DK1345597T3 (da) * | 2000-12-27 | 2007-12-10 | Ares Trading Sa | Amfifile lipidanopartikler til peptid- og/eller proteininkorporering |
| WO2003000236A1 (en) * | 2001-06-23 | 2003-01-03 | Lyotropic Therapeutics, Inc | Particles with improved solubilization capacity |
| KR100566911B1 (ko) * | 2001-06-25 | 2006-04-03 | 주식회사 삼양사 | 약물 전달체용 음이온기-함유 양친성 블록 공중합체 및 그의 양이온성 약물과의 복합체 |
| US7125568B2 (en) * | 2001-08-23 | 2006-10-24 | Sung Michael T | Lipophilic drug compositions |
| WO2003062372A2 (en) * | 2001-10-02 | 2003-07-31 | The Regents Of The University Of California | Nanoparticle assembled hollow spheres |
| US7311926B2 (en) * | 2002-12-20 | 2007-12-25 | Battelle Memorial Institute | Biocomposite materials and methods for making the same |
| WO2005048435A1 (de) * | 2003-11-13 | 2005-05-26 | Sew-Eurodrive Gmbh & Co. Kg | Kompaktantrieb |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
-
2004
- 2004-10-28 JP JP2006538369A patent/JP2007509981A/ja not_active Withdrawn
- 2004-10-28 NZ NZ546379A patent/NZ546379A/en unknown
- 2004-10-28 KR KR1020067007794A patent/KR20060097020A/ko not_active Ceased
- 2004-10-28 WO PCT/US2004/036172 patent/WO2005041933A1/en not_active Ceased
- 2004-10-28 US US10/977,926 patent/US20050170004A1/en not_active Abandoned
- 2004-10-28 EA EA200600877A patent/EA200600877A1/ru unknown
- 2004-10-28 AU AU2004285553A patent/AU2004285553B2/en not_active Ceased
- 2004-10-28 CA CA002541445A patent/CA2541445A1/en not_active Abandoned
- 2004-10-28 EP EP04796839A patent/EP1680087A1/en not_active Withdrawn
-
2006
- 2006-04-03 IL IL174748A patent/IL174748A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2004285553A1 (en) | 2005-05-12 |
| JP2007509981A (ja) | 2007-04-19 |
| AU2004285553B2 (en) | 2009-12-10 |
| KR20060097020A (ko) | 2006-09-13 |
| EA200600877A1 (ru) | 2006-12-29 |
| CA2541445A1 (en) | 2005-05-12 |
| WO2005041933A1 (en) | 2005-05-12 |
| US20050170004A1 (en) | 2005-08-04 |
| IL174748A0 (en) | 2006-08-20 |
| EP1680087A1 (en) | 2006-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2004285553B2 (en) | Nanoparticles for drug delivery | |
| Pandey et al. | A recent update: solid lipid nanoparticles for effective drug delivery | |
| Sawant et al. | Recent advances and patents on solid lipid nanoparticles | |
| Almeida et al. | Solid lipid nanoparticles as a drug delivery system for peptides and proteins | |
| EP2398488B1 (en) | Depot system comprising glatiramer acetate | |
| JP5513713B2 (ja) | 非層状分散を生じる組成物 | |
| US20060078618A1 (en) | Lipid particles and suspensions and uses thereof | |
| CN100431600C (zh) | 药物组合物 | |
| Rampaka et al. | Role of solid lipid nanoparticles as drug delivery vehicles on the pharmacokinetic variability of Erlotinib HCl | |
| AU2012343853A1 (en) | Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition | |
| Shah et al. | Lipid nanocarriers: Preparation, characterization and absorption mechanism and applications to improve oral bioavailability of poorly water-soluble drugs | |
| Farid et al. | Lipid-based nanocarriers for ocular drug delivery | |
| Patel et al. | Nanostructured lipid carriers-a versatile carrier for oral delivery of lipophilic drugs | |
| EP3416624B1 (en) | Process for the preparation of tolerizing immune-modulating particles | |
| Pandey | Solid lipid nanoparticles: a multidimensional drug delivery system | |
| US7611733B2 (en) | Nanoparticle formulations of platinum compounds | |
| CN102802616A (zh) | 聚精氨酸纳米胶囊 | |
| JP2002544177A (ja) | 脂質マトリックス−医薬結合体から産生された、活性剤の制御投与のための医薬ビヒクル | |
| USRE50301E1 (en) | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof | |
| MXPA06004675A (en) | Nanoparticles for drug delivery | |
| Thiruganesh et al. | Solid lipid nanoparticle and nanoparticle lipid carrier for controlled drug delivery–a review of state of art and recent advances | |
| Mitra | Lipid nano-particles in medicine: production, stability and drug delivery—A review | |
| CN101590018A (zh) | 依托泊苷固体脂质纳米粒及其制备方法 | |
| Keck et al. | Lipid nanoparticles (SLN, NLC, LDC) for the enhancement of oral absorption | |
| Seck | Lipid nanoparticles for therapeutic proteins delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed |